Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2024-02-11 04:27:27 ET Summary Ocular Therapeutix is using its Elutyx technology to develop drug candidates for eye disorders, with upcoming results from the HELIOS study for diabetic retinopathy Q2 2024. The company is also progressing with the phase 3 SOL study for wet age-relat...
2024-02-09 10:02:33 ET More on Ocular Therapeutix Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD Ocular wins FDA nod to change Phase 3 wet AMD trial design Biggest stock movers today: Moderna, Foot Locker, Adobe, Ocular Therapeutix and more ...
2024-02-09 02:51:35 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2024-02-08 06:48:31 ET Summary BRIUMVI sets the standard for CD20 administration with efficient twice-yearly 1-hour infusions. BRIUMVI should remain competitive with subcutaneous formulations. Whether or not BTKIs erode the long-term market for CD20s in coming years remains to...
2024-02-01 22:52:09 ET Start Time: 09:30 End Time: 11:31 Roche Holding AG (RHHBY) Q4 2023 Earnings Conference Call February 01, 2024, 09:30 AM ET Company Participants Thomas Schinecker - CEO Roche Group Teresa Graham - CEO Roche Pharmaceuticals Matt Sause...
2024-02-01 08:50:59 ET More on Roche Roche: Leveraging Nvidia's AI For Genentech's Innovation Roche Holding Non-GAAP EPS of CHF 18.57, revenue of CHF 58.72B; initiates FY24 outlook Roche ends AC Immune partnership for Alzheimer’s drugs Historical earni...
IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2023-10-31 Deluxe Corporation (DLX) is expected to report $0.62 for Q4 2023 SkyWest Inc. (SKYW) is expected to report $0.11 for Q4 2023 1-800-FLOWERS.COM Inc. (FLWS) is expected to report $1.22 for Q2 2024 Brook...
Roche Holding AG ADR (RHHBY) is expected to report $1.22 for Q4 2023
2024-02-01 03:48:34 ET More on Roche Holding: Roche: Leveraging Nvidia's AI For Genentech's Innovation Roche ends AC Immune partnership for Alzheimer’s drugs Roche, Remix Therapeutics sign license deal Historical earnings data for Roche Holding AG ...
2024-01-31 16:24:30 ET More on Viking Therapeutics Biotech And Pharma Diversification Pays Off Viking: Results From 2 Clinical Trials Of Weight Loss Drug Ahead, Other Catalysts On Tap Barron’s cites cancer and weight loss plays for biotech M&A Viki...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...